Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs, underpinned by its expertise in drug formulation and delivery. With a strong commitment to enhancing patient outcomes and a solid research framework, Kiora's strategic partnerships and clinical advancements underscore its potential within the biopharmaceutical sector, offering an attractive investment prospect for institutional investors looking to capitalize on the next generation of therapeutics.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$2.51
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 7, 2026 | $-0.62 | $-0.34 | Beat +45.2% | $-0.34 | $0 | $0 | — | 1D Pre+0.8% | On-Day+3.1% | 1D Post-2.3% |
Q ended Mar 31, 2026 Reported May 8, 2026 | $-0.71 | $-0.58 | Beat +18.3% | — | $0 | $0 | — | 1D Pre-2.4% | On-Day0.0% | 1D Post-1.6% |
Q ended Dec 31, 2025 Reported Mar 25, 2026 | $-0.44 | $-1.73 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $1.5M |
| $0 |
| -100.0% |
| 1D Pre+1.0% |
| On-Day-1.0% |
| 1D Post-3.4% |
Q ended Sep 30, 2025 Reported Nov 7, 2025 | $-0.06 | $0.01 | Beat +116.7% | — | $750.0K | $0 | -100.0% | 1D Pre-0.9% | On-Day+0.4% | 1D Post0.0% |